Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nature Clinical Practice Oncology · 2006-05 · 3 (5) · 269-280
DOI: 10.1038/ncponc0509 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nature Clinical Practice Oncology, 2006-05. Verfasst von Rita Nahta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030-4009, USA. rnahta@mdanderson.org. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm. Die Arbeit wurde bisher 691-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030-4009, USA. rnahta@mdanderson.org
Förderung
- NCI NIH HHS
Zitieren
APA
Nahta, R., Yu, D., Hung, M. C., Hortobagyi, G. N., & Esteva, F. J. (2006). Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice Oncology, 3(5), 269-280. https://doi.org/10.1038/ncponc0509
Vancouver
Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice Oncology. 2006;3(5):269-280. doi:10.1038/ncponc0509
BibTeX
@article{Nahta2006,
author = {Nahta, Rita and Yu, Dihua and Hung, Mien-Chie and Hortobagyi, Gabriel N and Esteva, Francisco J},
title = {Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer},
journal = {Nature Clinical Practice Oncology},
year = {2006},
volume = {3},
number = {5},
pages = {269--280},
doi = {10.1038/ncponc0509}
}
EUVIMED